Sign In
Buy COR
$263.64
-1.20 (-0.453%)
At Close: Jun 03, 2026
Scoop up These 3 GARP Stocks to Receive Handsome Returns
09:55am, Monday, 25'th Nov 2024
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. COR, RJF and CTAS are some stocks that hold promise.
Cencora Rallies 19.7% Year to Date: What's Driving the Stock?
10:16am, Friday, 22'nd Nov 2024
COR is gaining traction from the robust U.S. Healthcare Solutions segment, which raises optimism about the stock.
Are Medical Stocks Lagging Cencora, Inc. (COR) This Year?
10:45am, Tuesday, 19'th Nov 2024
Here is how Cencora (COR) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Here's Why Cencora (COR) is a Strong Growth Stock
10:45am, Wednesday, 13'th Nov 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?
10:15am, Wednesday, 13'th Nov 2024
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why Cencora (COR) is a Top Momentum Stock for the Long-Term
10:55am, Monday, 11'th Nov 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cencora Q4 Earnings & Revenues Beat Estimates, Margins Decline Y/Y
12:25pm, Wednesday, 06'th Nov 2024
COR's fourth-quarter fiscal 2024 results showcase a strong segmental performance.
Cencora Acquires Retina Care Practice Network For $4.6 Billion, Boosts Dividend On Better Than Expected Q4 Earnings
11:38am, Wednesday, 06'th Nov 2024
On Wednesday, Cencora, Inc.'s COR fourth-quarter 2024 sales increased 14.7% to $79.1 billion, beating the consensus of $77.65 billion.
Cencora, Inc. (COR) Q4 2024 Earnings Call Transcript
10:56am, Wednesday, 06'th Nov 2024
Cencora, Inc. (NYSE:COR ) Q4 2024 Earnings Call Transcript November 6, 2024 8:30 AM ET Company Participants Bennett Murphy - SVP, Head of IR Bob Mauch - President and CEO Laz Krikorian - SVP and CAO C
Here's Why Cencora (COR) is a Strong Value Stock
10:45am, Wednesday, 06'th Nov 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cencora (COR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
10:35am, Wednesday, 06'th Nov 2024
Although the revenue and EPS for Cencora (COR) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Stre
Cencora (COR) Tops Q4 Earnings and Revenue Estimates
08:46am, Wednesday, 06'th Nov 2024
Cencora (COR) came out with quarterly earnings of $3.34 per share, beating the Zacks Consensus Estimate of $3.21 per share. This compares to earnings of $2.86 per share a year ago.
Cencora to buy Retina Consultants of America for $4.6 bln
06:54am, Wednesday, 06'th Nov 2024
Drug distributor Cencora said on Wednesday it would acquire Retina Consultants of America (RCA) for $4.6 billion in cash, gaining access to its network of eye specialists.
Cencora Reports Fiscal 2024 Fourth Quarter and Year End Results
06:35am, Wednesday, 06'th Nov 2024
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2024 fourth quarter ended September 30, 2024, revenue increased 14.7 percent to $79.1 billion. Reve
Cencora Advances Specialty Leadership Through Acquisition of Retina Consultants of America
06:30am, Wednesday, 06'th Nov 2024
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has entered into a definitive agreement to acquire Retina Consultants of America (“RCA”), a leading management
